New Data Presented at the 2026 Peripheral Nerve Society (PNS) Annual Meeting

16 Jun, 2026 New Data Presented at the 2026 Peripheral Nerve Society (PNS) Annual Meeting

A post-hoc analysis of HELIOS-A demonstrated that vutrisiran and patisiran improved outcomes in patients with hATTR-PN regardless of baseline nerve conduction status, with those treated earlier in their disease course showing the greatest potential for disease reversal. Additionally, results of the NeuroFeeL study showed that neurofilament light chain (NfL) levels correlate with hATTR-PN disease severity, reinforcing NfL’s potential as a biomarker to support earlier diagnosis and clinical management.

Plante-Bordeneuve, et al. “RNAi efficacy in large and small fiber-predominant polyneuropathy of hereditary transthyretin amyloidosis: HELIOS-A post-hoc analysis”

Cauquil, et al. “Neurofilament light chain as a biomarker in patients with hereditary transthyretin amyloidosis with polyneuropathy”